MNKD
Price
$3.67
Change
+$0.08 (+2.23%)
Updated
Dec 7, 6:59 PM EST
82 days until earnings call
PDSB
Price
$5.12
Change
-$0.04 (-0.78%)
Updated
Dec 7, 6:59 PM EST
112 days until earnings call
Ad is loading...

Analysis and predictions MNKD vs PDSB

Header iconMNKD vs PDSB Comparison
Open Charts MNKD vs PDSBBanner chart's image
MannKind
Price$3.67
Change+$0.08 (+2.23%)
Volume$1.42M
CapitalizationN/A
PDS Biotechnology
Price$5.12
Change-$0.04 (-0.78%)
Volume$163.53K
CapitalizationN/A
View a ticker or compare two or three
MNKD vs PDSB Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
MNKD vs. PDSB commentary
Dec 08, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MNKD is a Hold and PDSB is a Hold.

COMPARISON
Comparison
Dec 08, 2023
Stock price -- (MNKD: $3.67 vs. PDSB: $5.12)
Brand notoriety: MNKD and PDSB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MNKD: 59% vs. PDSB: 32%
Market capitalization -- MNKD: $948.9M vs. PDSB: $183.54M
MNKD [@Biotechnology] is valued at $948.9M. PDSB’s [@Biotechnology] market capitalization is $183.54M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MNKD’s FA Score shows that 2 FA rating(s) are green whilePDSB’s FA Score has 0 green FA rating(s).

  • MNKD’s FA Score: 2 green, 3 red.
  • PDSB’s FA Score: 0 green, 5 red.
According to our system of comparison, MNKD is a better buy in the long-term than PDSB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MNKD’s TA Score shows that 6 TA indicator(s) are bullish while PDSB’s TA Score has 5 bullish TA indicator(s).

  • MNKD’s TA Score: 6 bullish, 3 bearish.
  • PDSB’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, MNKD is a better buy in the short-term than PDSB.

Price Growth

MNKD (@Biotechnology) experienced а +1.38% price change this week, while PDSB (@Biotechnology) price change was -2.66% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.23%. For the same industry, the average monthly price growth was +6.91%, and the average quarterly price growth was +25.39%.

Reported Earning Dates

MNKD is expected to report earnings on Feb 27, 2024.

PDSB is expected to report earnings on Mar 28, 2024.

Industries' Descriptions

@Biotechnology (+6.23% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for MNKD with price predictions.
OPEN
A.I.dvisor published
a Summary for PDSB with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
MNKD($949M) has a higher market cap than PDSB($184M). MNKD YTD gains are higher at: -30.361 vs. PDSB (-61.212). MNKD has higher annual earnings (EBITDA): 2.24M vs. PDSB (-48.62M). MNKD has more cash in the bank: 141M vs. PDSB (54.3M). PDSB has less debt than MNKD: PDSB (23.6M) vs MNKD (278M). MNKD has higher revenues than PDSB: MNKD (177M) vs PDSB (0).
MNKDPDSBMNKD / PDSB
Capitalization949M184M516%
EBITDA2.24M-48.62M-5%
Gain YTD-30.361-61.21250%
P/E RatioN/AN/A-
Revenue177M0-
Total Cash141M54.3M260%
Total Debt278M23.6M1,178%
FUNDAMENTALS RATINGS
MNKD vs PDSB: Fundamental Ratings
MNKD
PDSB
OUTLOOK RATING
1..100
7280
VALUATION
overvalued / fair valued / undervalued
1..100
4
Undervalued
62
Fair valued
PROFIT vs RISK RATING
1..100
47100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
7961
P/E GROWTH RATING
1..100
25100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNKD's Valuation (4) in the Biotechnology industry is somewhat better than the same rating for PDSB (62) in the Pharmaceuticals Major industry. This means that MNKD’s stock grew somewhat faster than PDSB’s over the last 12 months.

MNKD's Profit vs Risk Rating (47) in the Biotechnology industry is somewhat better than the same rating for PDSB (100) in the Pharmaceuticals Major industry. This means that MNKD’s stock grew somewhat faster than PDSB’s over the last 12 months.

PDSB's SMR Rating (99) in the Pharmaceuticals Major industry is in the same range as MNKD (100) in the Biotechnology industry. This means that PDSB’s stock grew similarly to MNKD’s over the last 12 months.

PDSB's Price Growth Rating (61) in the Pharmaceuticals Major industry is in the same range as MNKD (79) in the Biotechnology industry. This means that PDSB’s stock grew similarly to MNKD’s over the last 12 months.

MNKD's P/E Growth Rating (25) in the Biotechnology industry is significantly better than the same rating for PDSB (100) in the Pharmaceuticals Major industry. This means that MNKD’s stock grew significantly faster than PDSB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MNKDPDSB
RSI
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
83%
Momentum
ODDS (%)
Bullish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
78%
Bullish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 7 days ago
86%
Bullish Trend 22 days ago
85%
Declines
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 1 day ago
88%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
82%
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EZTGX39.16N/A
N/A
Eaton Vance Tx-Mgd Growth 1.2 C
TMLAX6.75N/A
N/A
Transamerica Energy Infrastructure A
JSIGX16.21N/A
N/A
Jacob Small Cap Growth Institutional
TQSIX19.80N/A
N/A
TRP Integrated US SMCC Eq I
DEMZX18.81N/A
N/A
Delaware Emerging Markets R6

MNKD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNKD has been loosely correlated with MDGL. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if MNKD jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNKD
1D Price
Change %
MNKD100%
+2.37%
MDGL - MNKD
49%
Loosely correlated
-0.32%
CRSP - MNKD
45%
Loosely correlated
-1.31%
AGIO - MNKD
44%
Loosely correlated
+2.62%
INSM - MNKD
44%
Loosely correlated
+1.14%
FOLD - MNKD
43%
Loosely correlated
+4.18%
More